Cannabis Law Report

SEPTEMBER 12, 2022

08, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed what it believes to be the largest legal natural psilocybin harvest in Canadian history. VANCOUVER, British Columbia, Sept. Penis Envy.

History 52

History Clinical Trials Legalization Research and Development 52

Cannabis Law Report

MAY 29, 2022

To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. Clinical Trials and Human Subject Protections. Here are the top five considerations: 1.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

MAY 14, 2022

13 May 2022. By 2022, it is now difficult to find a high street or retail centre between John o’ Groats and Land’s End without CBD products for sale. In addition to the regulatory barriers to access, funding has long been cited as a problem, with limited patient access through the UK’s National Health Service.

Access 52

Access CBD Research and Development Medicine 52

Veriheal

MARCH 23, 2023

Aside from Japan legalizing medical marijuana and forging a legal pathway that enables patients to use drugs made from cannabis plants, the amended legal law also seeks to criminalize the use of marijuana. Data suggests that the market has inflated from JPY4 billion (USD$3 billion) in 2019 to JPY17 billion (USD$13 billion) in 2022.

Legalization 66

Legalization Marijuana Clinical Trials Seed-To-Sale 66

Cannabis Law Report

AUGUST 18, 2022

As research into the use of psychedelic therapies continues to expand and additional data demonstrate significant positive outcomes in the treatment of mental health conditions, the benefits that psychedelics offer will continue to gain acceptance and understanding across the medical community. . BUFFALO, N.Y. , Aug. ” Joining Ms.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

The Cannigma

JUNE 23, 2022

The study also found that CBGA interacts with numerous other important receptors in the body like GPR55, TRPV1 channels, as well as GABA receptors, supporting further consideration and research for use in epileptic patients. He noted, “The data in the study isn’t really ready for translation to the clinic.” CBGA and COVID-19.

Cannabinoids 113

Cannabinoids Research and Development Clinical Trials Extraction 113

Cannabis Law Report

DECEMBER 6, 2021

“We look forward to Jeff’s significant contributions heading into another year of continued growth and progress for Goldfinch Bio, including a planned interim data readout from TRACTION-2, the ongoing Phase 2 clinical trial of our lead precision kidney medicine candidate, in mid-2022.”.

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. We expect to report this data as it becomes available and after submission to the FDA.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

AUGUST 10, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc. About Oravax Medical.

Clinical Trials 105

Clinical Trials Pharmaceutical Research and Development CBD 105

Project CBD

FEBRUARY 27, 2023

Instead, patients turn to a mix of whatever individual medications, therapies, and lifestyle changes (especially exercise) help ease symptoms and improve quality of life. “Available data strongly support the use of cannabinoids in treating fibromyalgia pain” due to “overwhelmingly positive treatment results.” It’s not a new idea.

THC 144

THC CBD Sleep Clinical Trials 144

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. Advancements in IP and Drug Development.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Veriheal

MAY 16, 2022

Following the successful experiment into the potential safety and efficacy of using ketamine for Parkinson’s patients, the university proceeded to sign an exclusive licensing partnership with Pharmather Inc. , Studying Ketamine Use for Parkinson’s Disease Patients. As many as 250 clinics across the U.S.

Research and Development 19

Research and Development Treatment Clinical Trials Patients 19

Cannabis Law Report

DECEMBER 20, 2021

First Patient Expected to be Enrolled by Q2 of 2022. Data To Support Regulatory Filings in the United States. a leading clinical trial services company, for a First in Human study investigating Epoladerm™ for pain associated with osteoarthritis of the knee. BERWYN, Pa.–(BUSINESS

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: [link] Accessed October 17, 2022. 2020;12(7):1935.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

DECEMBER 21, 2021

The rapid increase in the volume of enterprise data and growing automation of business processes across several end-use industries such as retail, manufacturing, healthcare, and transportation are expected to drive the demand for business software and services over the forecast period. billion in 2020 (Grandview Research). from 2021 to 2028.

Research and Development 52

Research and Development Supply Chain Data Business 52

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Third-party clinical studies investigating oral psilocybin have reported compelling anti-depressant effects. II is a $287.5

Therapy 52

Therapy Research and Development Business Access 52

The Cannigma

JANUARY 13, 2023

The fact that migraine is now ranked as the second leading cause of years lived with disability illustrates the magnitude of the negative impact of the disease to patients and their ability to function normally. A 2019 retrospective review of 316 patients found that medical cannabis improved the experience of 88.3%

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

JANUARY 3, 2022

Affirms expectations for initial topline results in 1H 2022. regulatory path; company expects to submit IND in 1Q 2022. Food and Drug Administration (FDA) during which the company received valuable guidance regarding the clinical development of ANEB-001 in the U.S. Recent FDA pre-IND meeting provides valuable guidance on U.S.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

NOVEMBER 29, 2021

Treatment-resistant depression – meaning patients have tried everything possible and did not find relief – is a harrowing condition affecting one in three people with depression – that’s a staggering one hundred million people worldwide for whom current depression treatments just don’t work. MADRS points from baseline to week three (vs.

Treatment 52

Treatment Clinical Trials Data Patients 52

Cannabis Law Report

NOVEMBER 26, 2021

Corporate and Clinical Development Highlights Include: Completed Patient Enrollment in Phase III Psoriasis Study – The Phase III Comfort™ study completed patient enrollment. Topline results are expected in Q1 2022. dollars in thousands (except for share and per share data). . . Financial Results.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Alchimia

JANUARY 25, 2022

At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. In the US, hopes of a quick federal cannabis legalisation in 2022 are fading, but a long shot such as cannabis having a major impact on COVID transmission or remission could speed things up.

Research and Development 98

Research and Development Terpenes CBD Treatment 98

The Cannigma

FEBRUARY 1, 2023

Patients are often left to their own devices when looking into cannabis and cancer, given the lack of clinical evidence, and stigma surrounding the use of the plant as medicine. To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer. The answer: Maybe!

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

NOVEMBER 15, 2021

The Company is developing this product candidate as a prophylactic treatment against SARS and influenza and has engaged Syneos Health to assist with the optimal clinical trial design. The FDA has indicated that Virpax may pursue an NDA drug approval with the Office of Non-Prescription Drugs. On September 9, 2021, Jeffrey A.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 12, 2021

Their audacious vision to reimagine traditional pharma efficacy trials promises to rapidly and accurately determine which nutraceuticals and natural molecules actually work for which conditions,” said Diamandis. Radicle Real World Sleep results will be announced in early 2022. “We

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

DECEMBER 7, 2021

A full report of the anonymized, aggregate findings will be released in early 2022. Initial findings indicate a significant number of participants experienced clinically meaningful improvements, meaning they realized distinct and palpable improvements in quality of life through improvements in the respective health outcomes studied.

Clinical Trials 52

Clinical Trials CBD Data Sleep 52

Cannabis Law Report

JULY 21, 2022

JULY 21, 2022. Department of Veterans Affairs (VA) and Indian Health Service (IHS) to provide recommendations and opinions regarding the medical use of cannabis by VA and IHS patients. Hopefully i’ll be dead by then. Booker, Schumer, Wyden Introduce Cannabis Administration and Opportunity Act.

Safety 52

Safety Legislation Clinical Trials Banking 52